Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The acquisition of SPR Therapeutics will allow Medtronic to expand its portfolio of neuromodulator medical devices. The deal is expected to close in 2027.
These third-party marketers earn commissions from their insurer clients not only upon initial signups but also every time “their” enrollees renew without changing plans.
The agency cited free speech as its reasoning for rescinding the long-standing policy. While in place, the rule barred companies that agreed to settlements with the Securities and Exchange Commission from publicly denying allegations made by regulators.
RadNet Chaiman and CEO Howard Berger, MD, explains why the company has invested tens of millions into DeepHealth to rapidly build up a new business model.
The company made the changes after its manufacturer rebates for insulin were challenged by the Federal Trade Commission. Among other shifts, Optum said 100% of all rebates will be distributed to customers by 2028.
Gen Xers and their elders tend to believe AI will do more harm than good. More than half of American adults 50 and older place themselves in that somewhat cynical category.
Over 97% of all counties in the U.S. see high or very high levels of consolidation in Medicare Advantage markets, with UnitedHealthcare and Humana owning the most plans nationwide.
Former Steward Health Care CEO Ralph de la Torre, MD, and other executives are accused in a $1.4 billion legal filing of paying themselves hundreds of millions of dollars in bonuses, despite the health system being insolvent.
In a new report, the New York Times details multiple incidents of the insurance giant using legal threats to silence social media users and news outlets, citing the murder of Brian Thompson and the threat of rising violence as the basis for its claims.
Shareholders of the retail pharmacy giant voted in favor of the terms of the sale to Sycamore Partners for $11.45 a share. The deal is expected to close later this year.